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Letter to the Editor
We read with interest the article by McCormack et al. about frequency and costs of hospitalisations of mitochondrial disorder (MID) patients in
California [1]. There are several reasons why the figures provided are underestimations.
First, quite a number of MIDs go undetected or are misinterpreted as another disease. Particularly, patients with multiorgan disease are fre-
quently in fact mitochondrial multiorgan disorder syndromes (MIMODSs) [2]. As soon as the cause of multisystem disease remains obscure, a MID
should be suspected and considered as a differential diagnosis. Since work-up of suspected MID is time-consuming, logistically demanding, cost-
intensive, and often associated with inconclusive or negative results, it is frequently not initiated at all, why many of these patients go undetected for
years or forever.
Second, ICD codes do not cover the entire spectrum of MIDs. For example, MIRAS, LBSL, or PCH may be missed. Even ICD10 does not cover all
specific and nonspecific MIMODS.
Third, coding of diagnoses is often insufficiently effectuated. Sometimes, only major diagnoses are encoded. Sometimes no ICD codes are al-
located at all.
Fourth, a number of congenital MIDs may remain undiagnosed because patients decease during the first few days or months of life. During this
short period it is often impossible to complete a comprehensive diagnostic work-up. Often these patients do not undergo autopsy.
Fifth, MIDs are often insufficiently diagnosed. According to various classification criteria, MIDs may be diagnosed as possible, probable, or
definite [3]. Often MIDs are only diagnosed upon histochemical or biochemical investigations, without the inclusion of functional or genetic studies.
Accordingly, we do not agree with the figure 1:4300 for the prevalence of MIDs [1]. Nonspecific MIDs are regarded much more frequent
occurring with a prevalence of 1:400 [4].
Overall, the costs in mitochondrial medicine will remain high if patients are misdiagnosed and thus mistreated. The longer a misdiagnosis is
maintained, the more costs incur.
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